All News
46 articles in total
Nuance Pharma's New COPD Drug Achieves Successful Phase III Study, Will File for Market Approval
Nuance Pharma has made significant progress in the development of drugs for chronic obstructive pulmonary disease (COPD). Its newly introduced inhaled drug, ensifentrine, showed excellent performance in its Phase III clinical trials in China, meeting all its pre-specified goals.
Continuous Flow Technology Revolutionizes API Synthesis: A Dual Breakthrough in Efficiency and Safety
Continuous flow technology, centered on microreactors, significantly reduces API synthesis time through highly efficient mass transfer and precise temperature control. It also mitigates risks of hazardous reactions at a physical level, bringing breakthroughs in both efficiency and safety to the pharmaceutical industry.
Two Leaders in the Global API Market: Outlook for China and India to 2025
The global active pharmaceutical ingredient (API) market is expected to reach US$347.9 billion in 2029. China and India, as the two major producers, are jointly shaping the global pharmaceutical supply chain with different strategies.
Global First Non-Opioid Painkiller Approved, Marking a Milestone Breakthrough in Pain Management
On January 30th local time, the U.S. FDA announced the approval of a new drug, Suzetrigine, from Vertex for the treatment of moderate to severe acute pain in adults.
GLP-1 Sector Explodes, Ushering in a Golden Opportunity for the Industry Chain
In 2024, the global demand for weight loss continues to be unleashed, leading to an explosive growth of GLP-1 drugs. This has also spurred the collective growth of related industries, such as medical consumables, APIs, and innovative drugs.
Synthetic and Natural APIs Jointly Drive the Future of Pharmaceutical Innovation
Active pharmaceutical ingredients are divided into two categories: synthetic and natural. These two categories differ significantly in their sources, production, and regulation. Rather than replacing one another, they complement and coexist, driving the diversified development of drug development.